Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-42160443 adjunctive therapy in inadequately controlled chronic low back pain
2009-009857-17Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic low back pain (CLBP) comparing JNJ-42160443 dose-ranging adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Average low back pain-related pain intensity score at end of 12-week double-blind efficacy phase. Started Jul 2009; status: terminated.
02
Drugs
fulranumab
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on 2009-009857-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009857-17.